BGB-900-103 : A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Female reproductive organs,Lung,Urinary systemKidney,Lung,Ovary,Renal cell carcinoma

Trial Overview Read MoreRead more

This phase I trial is combining an oral drug (sitravatinib) with an immuno-oncology drug (Tislelizumab) for the treatment of patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC) or Ovarian Cancer (OC).
 

This trial is treating multiple types of cancer including Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma or Ovarian Cancer .

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Commercial Sponsor

BeiGene Australia Pty Ltd

Summary

This is a non-randomised trial, in which patients will be allocated to one of five cohorts according to their tumor type and prior anti-programmed cell death protein-1 (PD-1)/PD-L1 antibody treatment. Cohort allocation is as described. Cohort A: Patients with anti-PD-1/PD-L1 antibody refractory/resistant metastatic, non-squamous NSCLC Cohort B: Patients with anti-PD-1/PD-L1 antibody naïve metastatic, non-squamous NSCLC. Cohort C: Patients with anti-PD-1/PD-L1 antibody refractory/resistant metastatic or advanced RCC. Cohort D (China-only): Patients with metastatic or advanced RCC without prior systemic therapy. Cohort E: Patients with anti-PD-1/PD-L1 antibody naïve recurrent and platinum resistant Epithelial OC.All cohorts will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Monash Health, Medical Oncology
Clayton
Early Phase Research Study Coordinator
earlyphase.oncresearch@monashhealth.org
0474 769 510

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next